Fewer breast cancers during post-treatment surveillance among patients initially staged using contrast-based imaging
Breast Cancer Research and Treatment · 2026
DOI: 10.1007/s10549-026-08049-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von T W W Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Breast Service, The Royal Melbourne Hospital, Parkville, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Mammography, Contrast Media, Carcinoma, Intraductal, Noninfiltrating. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Melbourne.
Abstract (Originalsprache)
Purpose
The role of contrast-based imaging (CBI) at diagnosis in early breast cancer remains debated. More sensitive baseline staging may identify synchronous disease that would otherwise present as early ipsilateral or contralateral events. We examined whether CBI at diagnosis is associated with differences in early locoregional outcomes.
Methods
A retrospective cohort study of women with early invasive breast cancer or ductal carcinoma in situ (DCIS). Patients were grouped according to whether they underwent CBI (CEM or MRI) at diagnosis. All underwent mammographic surveillance including contrast-enhanced mammography (CEM). Locoregional events from diagnosis to 30 June 2025 were identified and evaluated. Cox proportional hazards models to assess associations between CBI use and subsequent locoregional events were adjusted for age, calendar period, mammographic density (MD), and stage.
Results
Among 1,106 women (594 CBI, 512 non-CBI) diagnosed between April 2015 and June 2022, there were 60 locoregional events (39 invasive, 21 DCIS). Patients who underwent CBI had fewer subsequent locoregional events. After adjustment, CBI use at diagnosis was associated with significantly lower 5-year event rates among women with invasive cancer (adjusted HR 0.50, 95% CI 0.26–0.98, p = 0.043), particularly those with Luminal A/B phenotypes, low MD, and with fewer contralateral events in invasive index cases (adjusted HR 0.19, 95% CI 0.05–0.71, p = 0.014). Features of subsequent events (including tumour grade, behaviour, and invasive size) were not found to differ between groups.
Conclusion
Inclusion of CBI in local staging of early breast cancer was associated with lower rates of locoregional events over five years. These findings support broader consideration of CBI use for local staging at diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Breast Service, The Royal Melbourne Hospital, Parkville, Australia.
- Department of Radiology, The University of Melbourne, Parkville, Australia.
- Department of Surgery, The University of Melbourne, Parkville, Australia.
- Cancer Elimination Collaboration, Sydney School of Public Health, University of Sydney, Sydney, Australia.
- Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Australia.
- The Breast Service, The Royal Melbourne Hospital, Parkville, Australia. Bruce.Mann@mh.org.au.
Förderung
- University of Melbourne
Zitieren
APA
Yang, T. W. W., Rose, A. K., Matheson, J., Elder, K., MacCallum, C., Nickson, C., & Mann, G. B. (2026). Fewer breast cancers during post-treatment surveillance among patients initially staged using contrast-based imaging. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08049-6
Vancouver
Yang TWW, Rose AK, Matheson J, Elder K, MacCallum C, Nickson C, et al. Fewer breast cancers during post-treatment surveillance among patients initially staged using contrast-based imaging. Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-026-08049-6
BibTeX
@article{Yang2026,
author = {Yang, T W W and Rose, A K and Matheson, J and Elder, K and MacCallum, C and Nickson, C and Mann, G B},
title = {Fewer breast cancers during post-treatment surveillance among patients initially staged using contrast-based imaging},
journal = {Breast Cancer Research and Treatment},
year = {2026},
doi = {10.1007/s10549-026-08049-6}
}
EUVIMED